GlassScriptPhysician profile
Brandon A West
NPI 1750490660
$6,088.71
in general payments reported to CMS, 2019-2025
36 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $593 · 2021: $792 · 2022: $1,881 · 2023: $753 · 2024: $741 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.05 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Neuronetics, INC. | $983.29 | 2022 | |
| Lilly USA, LLC | $743.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $506.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $361.14 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $353.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.29 | 2019-2022 | |
| Pfizer INC. | $178.69 | 2019-2024 | |
| Allergan, INC. | $157.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $149.91 | 2019-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Xeris Pharmaceuticals, INC. | $146.02 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $144.46 | 2023-2025 | Veozah, Cresemba |
| Novartis Pharmaceuticals Corporation | $134.09 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $100.57 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $88.13 | 2024-2025 | Fanapt |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $83.25 | 2022 | |
| Harmony Biosciences LLC | $79.55 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $69.07 | 2020-2024 | Ajovy |
| Merck Sharp & Dohme LLC | $65.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.61 | 2021-2024 | Trintellix |
| Corcept Therapeutics | $40.31 | 2021-2022 | |
| Exact Sciences Corporation | $40.15 | 2023-2025 | Cologuard Collection Kit |
| Roche Diagnostics Corporation | $31.91 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.06 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $29.26 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.18 | 2021 | |
| Ironshore Pharmaceuticals INC. | $26.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.08 | 2023 | Spravato, Xarelto |
| Curonix LLC | $26.05 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Axsome Therapeutics, INC. | $20.04 | 2024 | Auvelity |
| Eisai INC. | $18.84 | 2021 | |
| Dexcom, INC. | $17.40 | 2025 | Dexcom G6 Transmitter |
| Adlon Therapeutics L.P. | $16.71 | 2020 | |
| Medtronic, INC. | $16.48 | 2023 | Minimed 780g |
| Tris Pharma INC | $15.90 | 2023 | Dyanavel Xr |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.